Testosterone Replacement Therapy Market Report 2026

The testosterone replacement therapy market size has grown steadily in recent years. It will grow from $2.11 billion in 2025 to $2.2 billion in 2026 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to increasing prevalence of hypogonadism, availability of oral testosterone formulations, growing geriatric population, rising awareness among urologists and endocrinologists, advancements in injectable testosterone therapies.

The testosterone replacement therapy market size is expected to see steady growth in the next few years. It will grow to $2.57 billion in 2030 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to development of novel transdermal gels and patches, growth in precision medicine approaches, increasing adoption of home-administered therapies, expansion of clinical research in testosterone deficiency, rising male fertility and wellness awareness. Major trends in the forecast period include personalized hormonal therapy, minimally invasive delivery methods, rising awareness of male hypogonadism, expansion of outpatient clinics and specialized endocrinology centers, growth of home-based testosterone therapy solutions.

The increasing prevalence of testosterone deficiency is expected to drive the growth of the testosterone replacement therapy market. Testosterone deficiency, also known as hypogonadism, occurs when the body is unable to produce sufficient levels of testosterone. Testosterone replacement therapy is used to restore testosterone levels to a physiological range, reversing the effects of hypogonadism and alleviating symptoms such as reduced libido, erectile dysfunction, depression, anemia, muscle loss, and more. For instance, in March 2024, PharmiWeb, an England-based media and technology company, reported that the estimated incidence of symptomatic testosterone deficiency in men aged 40-70 years ranges from 2.1% to 5.73%, with a prevalence as high as 38.7%. Therefore, the rise in testosterone deficiency is driving the growth of the testosterone replacement therapy market.

Major companies in the testosterone replacement therapy market are increasingly focusing on introducing testosterone cypionate injections to gain a competitive edge. Testosterone Cypionate Injection (USP) contains synthetic testosterone cypionate, a form of the naturally occurring male sex hormone. This injection is commonly prescribed as part of testosterone replacement therapy to address conditions related to testosterone deficiency, such as erectile dysfunction and hypogonadism. For example, in April 2023, Xiromed LLC, a US-based pharmaceutical company, launched Testosterone Cypionate Injection (USP). This injectable form of testosterone is used to treat low testosterone levels and related conditions, helping to restore testosterone to a healthy range. Testosterone cypionate injections are considered one of the most effective treatments for testosterone deficiency and are generally well-tolerated by patients.

In January 2024, Lipocine, Inc., a US-based biopharmaceutical company specializing in oral testosterone replacement therapies, partnered with Verity Pharma to expand the commercialization and market reach of its hormone-based treatments. The partnership aims to leverage Verity Pharma's regulatory and commercialization expertise to accelerate the market entry and adoption of Lipocine's oral testosterone replacement therapy, TLANDO, in the U.S. and Canada. Verity Pharma, a Canada-based specialty pharmaceutical company, focuses on the regulatory, marketing, and distribution of specialty therapeutics, including testosterone replacement therapies.

Major companies operating in the testosterone replacement therapy market are AbbVie Inc., Acerus Pharmaceuticals Corporation, Antares Pharma Inc., Bayer Aktiengesellschaft, BioTE Medical LLC, Clarus Therapeutics Inc., Eli Lilly and Company, Endo International plc, Pfizer Inc., Teva Pharmaceutical Industries Limited, Acrux Limited, Aytu BioPharma Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Bausch Health Companies Inc., Sandoz International GmbH, Besins Healthcare, Coloplast A/S, Recordati S.p.A.

North America was the largest region in the testosterone replacement therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the testosterone replacement therapy market report during the forecast period. The regions covered in the testosterone replacement therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the testosterone replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the testosterone replacement therapy market by increasing costs for imported raw materials and delivery devices, affecting product availability in regions reliant on international suppliers. Oral, parenteral, and gel/cream segments are particularly impacted, with North America and Europe seeing higher price pressures. Manufacturers are exploring local production and alternative sourcing to maintain supply chains. Positively, tariffs are incentivizing domestic innovation and localized manufacturing of testosterone therapies.

The testosterone replacement therapy market research report is one of a series of new reports that provides testosterone replacement therapy market statistics, including testosterone replacement therapy industry global market size, regional shares, competitors with a testosterone replacement therapy market share, detailed testosterone replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the testosterone replacement therapy industry. This testosterone replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Testosterone replacement therapy is a type of hormonal treatment used to address low testosterone (T) levels in males, which can occur due to aging or certain medical conditions.

The primary forms of testosterone replacement therapy include oral, implants, gels or creams, patches, buccal adhesives, parenteral, and other methods. Oral administration involves substances taken by mouth, such as tablets, capsules, syrups, and more. Low testosterone is typically treated in cases of hypogonadism, autoimmune conditions, genetic disorders, sex organ surgeries, and other related indications. Various active ingredients are used in these therapies, including testosterone, methyltestosterone, testosterone undecanoate, testosterone enanthate, and testosterone cypionate. These treatments are administered in hospitals, clinics, and other healthcare settings.

The testosterone replacement therapy market includes revenues earned by entities by providing hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy to treat low testosterone deficiency. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.